Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …

Background Among patients with resectable early-stage non–small-cell lung cancer (NSCLC),
a perioperative approach that includes both neoadjuvant and adjuvant immune …

Background Antibodies that block programmed death 1 (PD-1) protein improve survival in
patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in …

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors
(ICIs) is characterized by durable responses and improved survival in a subset of patients…

Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed
death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, …

Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome …

PurposeTreatment with programmed cell death-1 or programmed death ligand 1 (PD-(L) 1)
inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive …

Brain metastasis is an ominous complication of cancer, yet most cancer cells that infiltrate the
brain die of unknown causes. Here, we identify plasmin from the reactive brain stroma as a …

PD-1 blockade unleashes CD8 T cells 1 , including those specific for mutation-associated
neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell …

Background PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity.
Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody …